Compare Kinder Morgan Inc (KMI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Viatris Inc — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Kinder Morgan Inc is far larger — about 3.6× Viatris Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.66%). Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Viatris Inc for 57 Days on average.
| KMI | VTRS | |
|---|---|---|
Market Cap | $71.81B | $20.03B |
Volume | 16,921,908 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $34.31 | $18.27 |
52-Week Low | $25.84 | $9.74 |
Typical Hold Time | 150 Days | 57 Days |
Enterprise Value | $103.86B | $32.15B |
Dividend Yield | 3.66% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.25, up 1.35% with a bullish technical outlook. The company reported strong earnings beats in recent quarters with Q2 2026 EPS of $0.37 beating expectations of $0.32. Revenue grew to $16.94B in 2025 with improving profit margins. Analyst consensus shows mixed sentiment with 47% buy ratings and a $37.20 price target, representing 15% upside potential. Recent news highlights the company's $6B-$7B growth pipeline and resilience amid energy market volatility.
KMI presents a compelling investment case with stable fee-based revenues, dividend yield of approximately 4%, and strong project backlog. However, risks include high debt levels ($29.66B long-term debt), exposure to energy market volatility, and competitive pressures. The stock offers income and growth potential but requires monitoring of debt management and energy sector dynamics.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
